리가켐바이오
63,900KRWMarket close of 10/27 (Tue)
Down -1.54%-1,000KRWMarket close of 10/27 (Tue)
Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)66,200KRWUp +3.60%
Preliminary · replaced once official KRX data for the same date is published
- Open
- 65,600
- High
- 67,300
- Low
- 63,200
- Day range
- Day range low 63,200 high 67,300, open 65,600, close 63,900, previous close 64,900
- Volume
- 19×10K shares
- 12.1B KRW 0.78× the 20-session average
Market close of 10/27 (Tue)
Where it sits in the 1-year range
1%1-year close range 62,800 to 213,500 won, 1% up from the low
1% of the way up from the lowest close in 1 year (252 sessions) · -70.1% from the high
Loading
Free · no sign-inSource from 2021-05-17
Data dateMost recent closing data10/27 (Tue)
Market close data of 2026-10-27Points to check
- Earningsto check-205.7B KRWOperating income over the last four quarters -205.7B KRW (loss)
- Recent filingsnot verifiedCould not read filing data, so not verified
- Daily moveusual range-1.54%-1.54%, 0.4× the usual (20-session average ±3.72%)That day -1.54% · usual ±3.72% · large-move threshold ±7.4%
The other 2 are within the usual range
- Trading value0.8×usual range
- Foreign & institutional-2.0B KRWusual range
See the full check report
Same sector · 바이오 R&D
Down -0.67%· 26 of 64 stocks up, preferred shares excluded · trading value 190.2B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -12.6% | Flat 0.00% | 51.8B KRW |
| 올릭스 | Close over the last 20 sessions -11.8% | Down -5.72% | 24.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -8.3% | Up +0.37% | 14.0B KRW |
| 페니트리움바이오 | Close over the last 20 sessions -4.2% | Up +14.41% | 9.8B KRW |
| 보로노이 | Close over the last 20 sessions -19.3% | Down -2.86% | 8.9B KRW |
Schedule
- Q3 report due · 11/16 (Mon) · in 18 days
- Next data 10/29 (Thu) after 08:50
Related news
Loading
Tables, financials, investor flows and filing history are in the Detailed view.
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.